EUCTR2014-005309-18-Outside-EU/EEA进行中(未招募)不适用
A Ph III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® (DTwP-Hib-HepB Vaccine) when Administered to Indian Infants at 6, 10, and 14 Weeks of Age
ovartis Vaccines and Diagnostics0 个研究点目标入组 175 人开始时间: 2014年12月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male and female subjects = 42 days to = 64 days of age.
- •2.Written informed consent obtained from either parents/ legal guardian after the nature of the study has been explained according to local regulatory requirements
- •3.Subjects in good health as determined by the outcome of medical history, physical assessment and clinical judgment of the investigator
- •4.Available for all scheduled study visits
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 175
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subjects whose parents or legal guardians are unwilling or unable to give written informed consent to participate in the study.
- •2.History of previous immunization with a vaccine containing any of the 5 antigen components of investigational vaccine.
- •3.History of anaphylactic shock, urticaria or other allergic reactions after previous vaccination or known hypersensitivity to any vaccine component.
- •4.Known or suspected impairment of immune function, known HIV positivity, receiving immunosuppressive therapy, or having received systemic immunosuppressive therapy within 1 month prior to study entry (note: inhaled and topical steroids are allowed)
- •5.Administration of parenteral immunoglobulin preparation and/or blood products since birth
- •6.Planned administration of a vaccine not foreseen by the study protocol
- •7.Significant acute infection
- •8.Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives
- •9.Subject meeting with a nutritional status grades of I - IV according to the Indian Academy of Pediatrics (IAP) grading of nutritional status.
- •10.Participation in another clinical trial
研究者
相似试验
已完成
3 期
A clinical trial to Assess theImmunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine DTwP-Hib-HepB in Indian infantsCTRI/2011/11/002118ovartis Healthcare Pvt Ltd Vaccines Division175
进行中(未招募)
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.Chronic Lymphocytic LeukemiaEUCTR2016-001097-15-BGAbbVie Deutschland GmbH & Co. KG200
已完成
3 期
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL)Cancer of the blood10024324LeukemiaNL-OMON55465AbbVie B.V.8
进行中(未招募)
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.MedDRA version: 20.0Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic Lymphocytic LeukemiaEUCTR2016-001097-15-HUAbbVie Deutschland GmbH & Co. KG200
进行中(未招募)
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.MedDRA version: 20.0Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic Lymphocytic LeukemiaEUCTR2016-001097-15-PLAbbVie Deutschland GmbH & Co. KG200
